Member engagement in fundraising
The GI Cancer Institute is focused on raising awareness of GI cancers and... Read More
The GI Cancer Institute is focused on raising awareness of GI cancers and... Read More
Two options are better than one Rectal cancer affects more than 4,600 Australians every year. With 30% of people... Read More
RoLaCaRT-1 opening first sites We are thrilled to have RoLaCaRT-1 opening at five sites in the next week.... Read More
Today is GIST Awareness Day. It also marks Sarah McGoram’s 25th year of living with Gastro-Intestinal Stromal... Read More
With a rise in the number of colorectal cancer cases in people younger than 50, a US-based independent... Read More
The AGITG Upper GI and Lower GI Working Parties met in May to discuss respective concepts and trials. The Upper and Lower GI Working Party meetings are held every two months throughout the year, with members representing the disciplines of medical oncology, surgery, radiation oncology, statistics, translational science, study coordination... Read More
Congratulations to TOPGEAR The TOPGEAR trial in resectable gastric cancer has now completed patient recruitment! This... Read More
We are proud to announce Professor Chris Karapetis as the new AGITG Lower GI Working Party Chair and... Read More
The TOPGEAR trial in resectable gastric cancer has now completed patient recruitment! This significant milestone... Read More
MASTERPLAN trial Westmead Hospital has just been activated as a site for the MASTERPLAN pancreatic cancer clinical trial. MASTERPLAN... Read More
The third Idea Generation Workshop was held virtually on Friday 14 May, facilitated by Associate Professor Lara Lipton... Read More
A small trial that made a big difference for people with pancreatic cancer The GAP study challenged the prevailing... Read More
A breakthrough in advanced colorectal cancer treatment In the early 1990s, there was only one treatment available for advanced... Read More
Upper and Lower GI Working Parties We are pleased to welcome 18 new members to our Working Parties. Thanks... Read More
FORECAST-1 The FORECAST-1 has just four patients left to enrol, after opening only six months ago. FORECAST-1 aims to address... Read More
Improving survival for people with stomach cancer Clinical trials are constantly evolving as new insights come to light. The... Read More
First sites for INTEGRATE IIb to open soon The INTEGRATE II trial has transitioned to a INTEGRATE IIb after the study was updated to incorporate a promising new treatment. The purpose of INTEGRATE II was to determine whether regorafenib improved overall survival for people with advanced gastro-oesophageal cancer. INTEGRATE IIb... Read More
This year marks the 30th anniversary of the GI Cancer Institute and AGITG. This year, we are looking... Read More
This year marks the 30th anniversary of the GI Cancer Institute and AGITG. This year, we are looking... Read More
Building an online network of rare cancer clinicians and researchers to improve outcomes for patients Although there have been... Read More